{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-007361","form_type":"8-K","ticker":"ALXO","cik":"0001810182","company_name":"ALX ONCOLOGY HOLDINGS INC","filed_at":"2022-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.345855+00:00","generated_at":"2026-06-27T03:48:15.899563+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ALX Oncology reports Q4 2021 net loss $28.4M ($0.70/shr); cash $363.7M through mid-2024","bullets":["GAAP net loss Q4 2021: $28.4M ($0.70/shr) vs $18.8M ($0.50/shr) year ago; full year loss $83.5M ($2.07/shr).","R&D expenses Q4 $20.9M (incl. $4.7M ScalmiBio acquisition IPR&D) vs $12.1M year ago.","Cash $363.7M at Dec 31, 2021; runway through mid-2024.","FDA granted Orphan Drug Designation for evorpacept in gastric/GEJ cancer (Jan 2022).","Plan to initiate randomized Phase 2/3 ASPEN-06 trial in 2nd line gastric/GEJ cancer in 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-007361","json":"https://secwatch.observer/filing/0001564590-22-007361.json","markdown":"https://secwatch.observer/filing/0001564590-22-007361.md","text":"https://secwatch.observer/filing/0001564590-22-007361.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810182/000156459022007361/0001564590-22-007361-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810182/000156459022007361/alxo-8k_20220228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T03:48:15.899563+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}